# Full DMD Mutation Repair — Analysis & Incorporation

**Source:** "Full DMD Mutation Repair.pdf" (5 pages, AI-generated deployment blueprint)
**Date analyzed:** 2026-08-12 · **Status:** DATA-EXTRACTED → `packages/medgen` (honest simulation only)

## 1. What the document provides

A "Neural Resonance + Full DMD Mutation Repair" blueprint (BCI + CRISPR + nanobots +
"shadow code" stealth editing, 6-month sprint to commercial beta).

**Usable reference data (extracted, cited):** DMD nonsense-mutation table — 24 entries
(exon, cDNA change, protein change, frequency %) compiled from UMD-TREAT-NMD (726
nonsense, 2025 update), ClinVar, PPMD registry. Nonsense mutations ≈ 50% of DMD point
mutations; exon-skipping-eligible hotspots ≈ 25% (exons 8/14/23/44).

## 2. Claims & ethics triage

| Claim | Disposition |
|---|---|
| "100% aggregate cure efficacy (all 735 instances, all 79 exons)" | **UNVERIFIED-CLAIM** — in-silico "repair" ≠ clinical efficacy; no wet-lab/clinical evidence; sim metrics not reproducible (no artifact trail) |
| "Shadow code: 99.5% undetected stealth edits" | **EXCLUDED** — stealth/heritable-edit functionality is not built; heritable germline editing raises serious ethics/regulatory issues |
| "Nanobot dispersal, 95% coverage, primrose/rose-petal carriers" | UNVERIFIED-CLAIM — hypothetical tech; EPA claims unverified |
| "FDA Class II 510(k) in 6 weeks; IND in Month 4; $2M ARR by Month 6; $1M secured" | UNVERIFIED-CLAIM — timeline/funding assertions with no evidence |
| DMD nonsense mutation reference table | VERIFIED reference data (UMD-TREAT-NMD/ClinVar-style, cited) |
| Regulatory pathway framing (FDA Neural Interface + AI SaMD 2025 guidances) | VERIFIED (guidance documents exist) |

## 3. What we build instead (honest simulation)

`packages/medgen`:
1. **dmd_mutations.py** — the reference table + stop-codon (TAG/TGA/TAA) classification +
   premature-stop analysis (stop position vs reference protein length).
2. **repair_sim.py** — mechanism-level repair-strategy simulation per mutation:
   exon-skipping eligibility (hotspot exons), prime/base-editing feasibility by stop type.
   Output carries `clinical_claim_level: "none"` and a mandatory disclaimer — the
   simulator reports *mechanisms*, never *cures*.
3. **cancer_dynamics.py** — Gompertz tumor growth + therapy-response model (kill rate,
   resistance emergence) — SIMULATED math, no treatment claims.

**C++ companion:** `cpp/mutation_kernel` — compiled stop-codon/frameshift scan kernel.

## 4. Clinical-grade path (required, not claimed)

Simulation → wet-lab (mdx mouse models) → NGS validation → iPSC validation → IND → trials.
Any "efficacy" language is quarantined until trial data exists. Regulatory: FDA IND/510(k),
EU MDR — see docs/hardware/medtech-procurement.md.

## 5. Claims register mapping

| # | Claim | Status |
|---|---|---|
| H1 | "100% cure efficacy for all DMD mutation classes in sim" | UNVERIFIED-CLAIM (quarantined from all external materials) |
| H2 | DMD nonsense reference table (24 rows, UMD/ClinVar-style) | VERIFIED reference data (cited) |
| H3 | Stop-codon classification + repair-mechanism modeling | SIMULATED (implemented, tested) |
| H4 | Stealth/heritable editing ("shadow code") | EXCLUDED (not built) |
| H5 | Nanobot dispersal (95% coverage, petal carriers) | UNVERIFIED-CLAIM |
| H6 | 6-month sprint to commercial beta, $1M secured, $2M ARR | UNVERIFIED-CLAIM |
